InvestorsHub Logo
Followers 83
Posts 5662
Boards Moderated 1
Alias Born 10/17/2006

Re: Phaeton post# 6630

Tuesday, 09/02/2014 12:15:03 PM

Tuesday, September 02, 2014 12:15:03 PM

Post# of 32022
Let’s assume that the drug generates $300 million in profits, and because usually at least the first one-third or so of a “milestone” package is meant to be fairly easily attained, let’s also assume that in the process of getting to $300 million, at least a half of that first third is triggered (and, to keep the math simple, we’ll assume the milestone package was for $750 million rather than $775 million).

In this case, MannKind will be receiving it’s cut of the $300 million ($105 million)… plus one-half of one-third of the milestone package (so half of $250 million, or $125 million)… plus the $150 million it received upfront… bringing us to a grand total of $380 million for a drug that generated $300 million in sales!

What a serious joke that article is! They act like 300 million in sales is 100% profit. Probably 300 million in sales generates zero profit after sales, marketing and start-up costs.

It's a real shame that people are publishing such obvious fake stuff to pump this stock
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MNKD News